Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.

Item

http://www.wikidata.org/entity/Q35784197

Q35784197

about

Immune mechanisms in malaria: new insights in vaccine development A review of malaria vaccine clinical projects based on the WHO rainbow table Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age Vaccines for malaria: how close are we?Malaria vaccine clinical trials: what's on the horizon Vaccine platforms combining circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responses Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies.Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.The RTS,S vaccine candidate for malaria.A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein.The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.Vaccine Potentiation by Combination Adjuvants Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes Using Hematology Data from Malaria Vaccine Research Trials in Humans and Rhesus Macaques (Macaca mulatta) To Guide Volume Limits for Blood Withdrawal.Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform.Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1 Plasmodium falciparum malaria vaccines in development.Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells Cryptosporidium hominis gene catalog: a resource for the selection of novel Cryptosporidium vaccine candidates.Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.Adenovirus RID-alpha activates an autonomous cholesterol regulatory mechanism that rescues defects linked to Niemann-Pick disease type C.Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects.Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection.Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria.

P2860

Q21032484-B3457A42-AAD6-45F7-A328-F2E0A26BD94A Q21034112-EE66F856-31F6-4E18-BE3F-4BBD5EAFD496 Q24273364-6C823F70-3C60-4B4A-8537-3303680C9628 Q24658073-F87C03B1-702F-4225-AFFD-CD87D3A03A4D Q27024344-3F0ED63E-ABF4-47F2-82B0-9C631CB67A50 Q28083110-7593401A-C73D-40A9-BE4F-E9CC7D31BD76 Q28740832-1B7BC8FB-E30F-48C2-8639-117047EB048C Q28744136-55E3647E-6B27-4675-AD70-4CBEE7047D81 Q28744149-63A3086C-72E0-40AE-B309-A365428D6AA8 Q33316023-DA69ADEF-9A5A-47EF-9187-8ACD8F830D6F Q33492290-51D3F8F7-BB36-4F15-B157-F634F4DC6999 Q33521372-03CDB63B-2BFD-4D06-82F6-B4151470EB80 Q33950119-0700FB7C-361C-446D-9197-356382E9F029 Q34128586-F09836FA-A7CE-4EA8-AFEA-0EEB21832665 Q34170122-794B3274-B977-44B6-84E8-F9FFA9836C95 Q34186762-5DC7E10F-D993-4A37-9890-82003973FB86 Q34232909-9A6B1F5B-01E8-4832-BC78-AF65114173BE Q34274515-F624D656-9E43-422E-B3B1-4D7D33F35084 Q34289823-AB8ADAF8-9488-4EA1-A014-0DDDF97C37C8 Q34416103-440733F7-846C-4809-BE15-1F91726917CD Q34600955-0ABFA5C0-B350-404F-9770-FD7C8C000664 Q35045424-87DD17B8-A9C2-485B-BBE7-ACF9209E48B8 Q35177864-D69E1F0A-33C2-4A41-B03A-24872D299E01 Q35684141-8B3E9739-7A04-4BFD-916C-8690626E2D34 Q35826767-488689C6-8D0B-4E9B-A435-F4A7AC251195 Q36114395-21BD5871-CC2E-40C3-8EEA-6B17D1E624AE Q36151198-A492A645-F7A0-4175-A12F-7AD0063E4F92 Q36311802-4B5B95AE-AD76-40E9-8EB8-A253B7723929 Q36330007-69749D75-7554-4A63-9C34-466666468AE2 Q36539553-CD028665-C517-4CFB-B30B-FFA58AB72ADE Q37103927-0209C04F-0E79-4DE0-8966-44BA0B2D5334 Q37218080-B380D87C-EF71-482F-B2A4-5A0FF730B508 Q37350955-421B3914-6308-4B02-82B7-882B50324D5C Q37355917-6B4F9C61-38FE-4902-AF92-851E4D0B5B73 Q37425577-AD98B71A-0205-4B6C-9A10-A12C44D6CD90 Q37461371-504FEE12-2B2C-4014-9A49-F4939DD1D906 Q37696415-E06A14AB-F8F3-457F-BF13-B86483A283D3 Q37742680-8474B4A1-631A-4B71-8B39-C53DBF672332 Q37867102-B5844032-6638-47F0-A501-8AD120D5276C Q37924616-25D38711-3AB8-4272-A320-0A2B49DD24E2

P2860

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.

Item

http://www.wikidata.org/entity/Q35784197

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Priming with an adenovirus 35- ...... either malaria vaccine alone.

@ast

Priming with an adenovirus 35- ...... either malaria vaccine alone.

@en

type

Item

label

Priming with an adenovirus 35- ...... either malaria vaccine alone.

@ast

Priming with an adenovirus 35- ...... either malaria vaccine alone.

@en

prefLabel

Priming with an adenovirus 35- ...... either malaria vaccine alone.

@ast

Priming with an adenovirus 35- ...... either malaria vaccine alone.

@en

P1476

Priming with an adenovirus 35- ...... either malaria vaccine alone.

@en

P2093

Babak Bayat

http://www.w3.org/2001/XMLSchema#string

D Gray Heppner

http://www.w3.org/2001/XMLSchema#string

David Larson

http://www.w3.org/2001/XMLSchema#string

Gerrit Jan Weverling

http://www.w3.org/2001/XMLSchema#string

J Robert Burge

http://www.w3.org/2001/XMLSchema#string

Jerome H H V Custers

http://www.w3.org/2001/XMLSchema#string

Joe Cohen

http://www.w3.org/2001/XMLSchema#string

Joseph Shott

http://www.w3.org/2001/XMLSchema#string

Lisa A Ware

http://www.w3.org/2001/XMLSchema#string

Maria G Pau

http://www.w3.org/2001/XMLSchema#string

P2860

The global distribution of clinical episodes of Plasmodium falciparum malaria

Intravital observation of Plasmodium berghei sporozoite infection of the liver

Central memory and effector memory T cell subsets: function, generation, and maintenance

Improved adenovirus vectors for infection of cardiovascular tissues

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen

Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.

The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites.

Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.

Adenoviruses as vaccine vectors.

P304

2283-2290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.01879-06

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jaap Goudsmit

P577

2007-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6497553

http://www.w3.org/2001/XMLSchema#string

P698

17307942

http://www.w3.org/2001/XMLSchema#string

P921

malaria

Adenoviridae

Plasmodium falciparum

P932

1865796

http://www.w3.org/2001/XMLSchema#string

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.

about

P2860

P2860

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932